Since the beginning of May, the stock, which hit the Rs 1-trillion market capitalisation last month, has gained 40 per cent. The outperformance over a three-month period over its peer index (BSE FMCG) and benchmarks (Nifty50) has been sharp with gains that are four times those of the indices.
Given the performance in the June (Q1FY22) quarter and growth outlook, investors’ enthusiasm for the stock does not seem to be misplaced. The company reported a better than expected 24.4 per cent growth in revenues over the year-ago quarter. The volume growth of 15 per in the domestic business powered the top line with the personal and home care segments (17-21 per cent) standing out on the growth parameter. Even on a two-year compound annual growth rate (CAGR) basis, growth at 12 per cent in the domestic market is the highest among peers in the home and personal care businesses.
The domestic market accounted for 57 per cent of consolidated revenues.
Within the home care business, the household insecticides segment, which accounts for over 80 per cent of revenues in that area, delivered double-digit growth with good demand across premium (aerosol, electric, non-mosquito) and burning formats. In addition to tackling the illegal incense sticks, the company launched Goodknight Jumbo Fast Card in Maharashtra.
In international operations, while the Africa business reported its fourth consecutive quarter of double-digit growth, the performance in Indonesia was disappointing. The geography reported flat y-o-y growth due to the pandemic and an adverse macroeconomic environment.
Commenting on revenue growth, Richard Liu and Vicky Punjabi of JM Financial say the two key important monitorables of India home care and Africa have delivered healthy steady-state sales growth (two-year CAGR), which is a key positive, given the prolonged weakness on these fronts in the recent past.
While revenue growth has been strong, the outperformance was higher at the operating profit level. Even as gross margins contracted by 210 basis points due to raw material inflation (higher palm oil prices and a lag in price hikes), the company posted a 40 basis point expansion in operating profit margins to 20.7 per cent.
While there is all-round growth across geographies and segments, the rerating triggers for the stock, according to analysts led by Himanshu Nayyar of YES Securities, are portfolio scale‐up in under penetrated categories like household insecticides and hair colour, entry into newer categories in India, and pruning down some unprofitable international businesses along with recent leadership changes.
A majority of analysts have a buy rating, but given the target price of Rs 1,034, there is limited upside from the current price. Investors should await a meaningful correction before considering the stock, which is trading at 44 times its FY23 earnings estimates.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in